In sum, the prognostic importance of CDKN2A/B homozygous deletion in IDH-mutant glioma begs the question of how this genetic alteration impacts the biology of IDH mutation in relation to patient survival, and, importantly, how to develop a coherent strategy for the treatment of IDH-mutant glioma. The gene discussed is IDH2; the disease is glioma.